<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573833</url>
  </required_header>
  <id_info>
    <org_study_id>07-120</org_study_id>
    <secondary_id>MSKCC-07120</secondary_id>
    <nct_id>NCT00573833</nct_id>
  </id_info>
  <brief_title>Internal Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near
      a tumor to kill tumor cells.

      PURPOSE: This clinical trial is studying the side effects and how well internal radiation
      therapy works in treating patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the feasibility of high-dose rate (HDR) brachytherapy (without the use of
           external-beam radiotherapy) as definitive treatment for patients with intermediate-risk
           prostate cancer.

        -  To assess acceptable toxicity, defined as treatment related toxicity (urinary and
           rectal), no worse than that seen by patients treated with conventional therapy (grade 3
           urinary toxicity &lt; 10% and grade 3 rectal toxicity &lt; 10%).

      Secondary

        -  To achieve adequate dosimetric coverage of the prostate comparable to current standards.

        -  To assess the effect of treatment on sexual function.

      OUTLINE: Patients undergo 4 high-dose rate brachytherapy treatments over 2 days.

      Patients complete bladder, bowel, sexual function, and quality of life questionnaires,
      including the International Index of Erectile Function (IIEF) questionnaire, the
      International Prostate Symptom Score Index (IPSS), and the MSKCC Prostate Quality of Life
      questionnaire at baseline and then at every follow-up visit.

      After completion of study treatment, patients are followed every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With an Acceptable Level of Severe Toxicity as Defined at &lt; Grade 3 CTC Toxicity</measure>
    <time_frame>At scheduled 3 month intervals for one year</time_frame>
    <description>Feasibility will be defined as an acceptable level of severe toxicity (both acute and late effects), and adequate dosimetric coverage. Severe toxicity will be defined as &gt; or = grade 3 NCI CTC toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an Acceptable Level of Treatment Related Urinary and Rectal Toxicity as Defined at &lt; Grade 3 CTC Toxicity</measure>
    <time_frame>Within 90 days of treatment (early toxicities) or after 90 days (late toxicities)</time_frame>
    <description>urinary and rectal toxicity-see the adverse event tables</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint</measure>
    <time_frame>week 12 reported</time_frame>
    <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the number of participants who return to normal erectile function (IIEF-EF domain score ≥26)</description>
  </other_outcome>
  <other_outcome>
    <measure>Median International Prostate Symptom Total Score</measure>
    <time_frame>week 12 reported</time_frame>
    <description>Quality of life will be assessed with the MSKCC prostate quality of life instrument. International prostate symptom score index (IPSS). The IPSS index is a seven item questionnaire designed to assess urinary functioning, specifically urinary frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency. Questions are rated on a six point Likert scale with higher scores indicating more difficulty in urinary functioning. This measure demonstrated a high internal consistency (Cronbach's alpha = 0.84) with excellent test-retest reliability (r = 0.92).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Intermediate-risk adenocarcinoma of the prostate, defined by 1of the following
             criteria:

               -  PSA 10-20 ng/mL

               -  Gleason score ≥ 7

               -  Stage ≥ T2b AND &lt; T3

          -  Less than 20% risk of seminal vesicle involvement or lymph node involved based upon
             the Kattan nomogram (pre-treatment risk with IMRT)

          -  Prostate size &lt; 60 cc by MRI or CT imaging

          -  International Prostate Symptom Score Index ≤ 15

        Exclusion criteria:

          -  Evidence of definitive extracapsular extension/seminal vesicle invasion or pelvic
             adenopathy by MRI (endorectal coil) and DRE (digital rectal examination)

               -  Suspected extracapsular disease will not be considered an exclusion criteria

          -  PSA &gt; 20 ng/mL

          -  Presence of distant metastases

        PATIENT CHARACTERISTICS:

          -  WBC ≥ 3,500/mm³

          -  Platelet count ≥ 75,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  Liver function tests ≤ 1.5 times normal

          -  INR ≤ 2.5

          -  Able to complete quality of life questionnaires

          -  Able to give informed consent

          -  No active perineal infections

          -  No history of urethral stricture

          -  No prior history of pelvic malignancy

          -  No prior history of lymphoma disease, ulcerative colitis, or anal fissures

          -  No contraindications to general anesthesia

          -  No pacemaker

        PRIOR CONCURRENT THERAPY:

          -  No prior transurethral resection of the prostate

          -  No prior pelvic radiotherapy

          -  No prior treatment for prostate cancer except for hormone therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Yamada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherri M. Donat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Zaider, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2017</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HDR Brachytherapy</title>
          <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HDR Brachytherapy</title>
          <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an Acceptable Level of Severe Toxicity as Defined at &lt; Grade 3 CTC Toxicity</title>
        <description>Feasibility will be defined as an acceptable level of severe toxicity (both acute and late effects), and adequate dosimetric coverage. Severe toxicity will be defined as &gt; or = grade 3 NCI CTC toxicity</description>
        <time_frame>At scheduled 3 month intervals for one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDR Brachytherapy</title>
            <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Acceptable Level of Severe Toxicity as Defined at &lt; Grade 3 CTC Toxicity</title>
          <description>Feasibility will be defined as an acceptable level of severe toxicity (both acute and late effects), and adequate dosimetric coverage. Severe toxicity will be defined as &gt; or = grade 3 NCI CTC toxicity</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an Acceptable Level of Treatment Related Urinary and Rectal Toxicity as Defined at &lt; Grade 3 CTC Toxicity</title>
        <description>urinary and rectal toxicity-see the adverse event tables</description>
        <time_frame>Within 90 days of treatment (early toxicities) or after 90 days (late toxicities)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDR Brachytherapy</title>
            <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Acceptable Level of Treatment Related Urinary and Rectal Toxicity as Defined at &lt; Grade 3 CTC Toxicity</title>
          <description>urinary and rectal toxicity-see the adverse event tables</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint</title>
        <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the number of participants who return to normal erectile function (IIEF-EF domain score ≥26)</description>
        <time_frame>week 12 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDR Brachytherapy</title>
            <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint</title>
          <description>Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the number of participants who return to normal erectile function (IIEF-EF domain score ≥26)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median International Prostate Symptom Total Score</title>
        <description>Quality of life will be assessed with the MSKCC prostate quality of life instrument. International prostate symptom score index (IPSS). The IPSS index is a seven item questionnaire designed to assess urinary functioning, specifically urinary frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency. Questions are rated on a six point Likert scale with higher scores indicating more difficulty in urinary functioning. This measure demonstrated a high internal consistency (Cronbach’s alpha = 0.84) with excellent test-retest reliability (r = 0.92).</description>
        <time_frame>week 12 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDR Brachytherapy</title>
            <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median International Prostate Symptom Total Score</title>
          <description>Quality of life will be assessed with the MSKCC prostate quality of life instrument. International prostate symptom score index (IPSS). The IPSS index is a seven item questionnaire designed to assess urinary functioning, specifically urinary frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency. Questions are rated on a six point Likert scale with higher scores indicating more difficulty in urinary functioning. This measure demonstrated a high internal consistency (Cronbach’s alpha = 0.84) with excellent test-retest reliability (r = 0.92).</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HDR Brachytherapy</title>
          <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
questionnaire administration
quality-of-life assessment
brachytherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary-Other Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary retention (includ neurogenic bladder)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculatory dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Josh Yoshiya Yamada, Assistant Attending</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>+1212-639-2950</phone>
      <email>yamadaj@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

